FindTrial
Sign In

Role of host factors in predicting antiviral response in chronic hepatitis C

Role of Serum Vitamin D levels and Interleukin-28Brs12979860 C/T Polymorphism in Predicting Antiviral Response in Chronic Hepatitis C

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/07/005992
Enrollment
61
Registered
2015-07-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic hepatitis C patints

Interventions

Intervention1: Vitamin D: vitamin D3 was given orally at a dose of 2000 IU once daily from day 0 and continued for 48 weeks. Control Intervention1: NIL: NIL

Sponsors

Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: age 18-65 years, a chronic HCV genotype 1 and 4 infection with detectable HCV RNA for 6 month and no previous treatment for hepatitis C

Exclusion criteria

Exclusion criteria: Patients with advanced cirrhosis (Child-Pugh B or C), presence of hepatocellular carcinoma, human immunodeficiency and hepatitis B coinfection, , autoimmune liver disease , Wilson disease, hemochromatosis , α1-anti trypsin deficiency, concomitant use of medications known to affect serum vitamin D metabolism, and patients with active intravenous drug addiction

Design outcomes

Primary

MeasureTime frame
Primary outcome was defined as sustained virologic response ,defined as undetectable HCV RNA 6 months after completion of therapyTimepoint: 6 month after completion of therapy—

Secondary

MeasureTime frame
Secondary outcome was defined as undetectable HCV RNA at 4,12 and 48 weeks of therapyTimepoint: 4,12,48 weeks—

Countries

India

Contacts

Public ContactManas Kumar Behera

Banaras Hindu university

akjainbhu@gmail.com9415353097

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026